Sunil Kumar/LinkedIn
Dec 17, 2025, 23:37
Sunil Kumar: Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024)
Sunil Kumar, Entrepreneur of Medifit Devices LLP, shared a post on LinkedIn:
“Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024).
Rare diseases may affect smaller patient populations, but strong science, high unmet need, and long term therapy adoption continue to translate into meaningful revenues. From enzyme replacement therapies to advanced coagulation factors, these products underline the commercial strength of rare disease portfolios.
The list highlights reported 2024 revenues along with primary approved indications across areas such as amyloidosis, hemophilia, and inherited metabolic disorders.”
Stay updated with Hemostasis Today.
-
Sep 12, 2026, 07:02Melissa Hollo: Pre-Operative Anemia – An Underrecognized Challenge in Surgical Care
-
Sep 12, 2026, 06:57Klaus Metzeler: ESH 2026 MDS Conference – Connecting Experts Across Hematology
-
Sep 12, 2026, 06:40Lakmali Silva: Fibrinolysis and Its Role in Hematopoietic Recovery After Chemotherapy
-
Sep 12, 2026, 06:30Alexander Misono: Improving DVT Diagnosis and Care Through Venous Duplex Ultrasound
-
Sep 12, 2026, 06:06Simone Cesaro: GNE-Related Thrombocytopenia – New Findings
-
Sep 12, 2026, 04:11Jyotishbhai Patel: Why India Needs Universal Newborn Screening for Sickle Cell and Thalassemia
-
Sep 12, 2026, 04:04Oliver Schlager: New ESC and ESVM Clinical Consensus on Lipid-Lowering Therapy in VTE
-
Sep 12, 2026, 03:54Toby Richards: Representing IronLife at Parliament on Anaemia and Iron Deficiency
-
Sep 12, 2026, 03:50Saleh Shamse Basha: When ‘Low Protein S’ Isn’t Necessarily Low